Search

Background: No ideal radiopharmaceutical exists for positron emission tomography (PET) that fulfills all clinical requirements for the study of brain tumors., Purpose: The usefulness of a recently developed PET tracer, [methyl-11C]thymidine ([methyl-11C]TdR) is explored in brain tumors., Patients and Methods: Twenty patients with confirmed tumoral and non-tumoral brain lesions were investigated with [methyl-11C] TdR PET. The 11C activity was visually and quantitatively assessed. In two patients, dynamic scans were performed. The PET findings were compared to those of magnetic resonance imaging (MRI) or computed tomography (CT) of the brain and to the final diagnosis., Results: Eight out of ten patients with confirmed tumoral lesions or tumor recurrence had increased 11C activity within the lesion. In ten non-tumoral lesions no increased 11C uptake was found. The dynamic PET studies showed that [methyl-11C] TdR first acts as a blood flow tracer, but that later on the uptake of 11C activity is due to labeled metabolites, crossing the blood-brain barrier. Increased tracer activity was only observed in tumoral and not in non-tumoral contrast-enhanced lesions on MRI or CT., Conclusions: [Methyl-11C] TdR is not a selective PET radiopharmaceutical for brain tumors, but can be used as a tracer for tumoral blood-brain barrier disruption.

Two patients presenting with progressive dysarthria as the single initial manifestation of a neurodegenerative condition are described. The nature of the dysarthria as well as the additional symptoms that developed in the course of the disorder are very different in these two cases. Nevertheless, neuroimaging findings are strikingly similar and suggest bilateral involvement of posterior inferior frontal lobe structures, mainly in the dominant cerebral hemisphere. The clinical syndrome of these patients can therefore be considered an example of frontotemporal degeneration presenting without dementia or compartmental alteration, at least in the early stages. This broadens the clinical spectrum of frontotemporal degeneration and demonstrates the need for a syndromal subclassification of this nosological entity.

Cobalt-55 (55Co) is a positron emission tomography (PET) tracer used to demonstrate brain damage, possibly associated to calcium-mediated processes. The degree of 55Co accumulation correlates with the severity of ischaemia in stroke patients. It is still a matter of debate whether ipsilateral thalamic hypometabolism (ITH) and crossed cerebellar hypometabolism (CCH), occurring after middle cerebral artery (MCA) infarcts, represent only a metabolic depression of these remote regions or can lead to structural damage. The present study investigates whether an increased 55Co influx can be demonstrated with PET in ITH and CCH after MCA infarcts. About half of the patients with ITH and CCH had a significant degree of 55Co uptake in, respectively, the ipsilateral thalamus and the contralateral cerebellar hemisphere. It was observed in patients with severe signs of stroke on admission and poor clinical outcome, and correlated well with the degree of 55Co influx within the supratentorial infarct. The present study demonstrates that ITH and CCH after MCA infarction can represent structural damage in these remote areas that occurs during the second week after stroke onset.

Unlabelled: Previous studies have shown the usefulness of divalent cobalt isotopes to visualize cerebral damage after stroke. The site of accumulation of cobalt ion is unknown but may be explained by neuronal influx, analogous to that of calcium ion. Additionally, uptake may be due to infiltrating leukocytes or protein-bound cobalt. The aims of this study were to compare 57Co-SPECT with leukocyte SPECT and to compare the SPECT findings with clinical outcome as scored by the Orgogozo scale., Materials: Ten patients with a CT scan positive for middle cerebral artery infarcts were included in the study (7 men, 3 women; mean age 70 yr). Technetium-99m leukocyte and cobalt-SPECT (interval 2-4 days) were made with a double-headed gamma camera, after the injection of 10-15 mCi 99mTc-HMPAO-labeled leukocytes and 0.4 mCi 57Co, respectively. Scans were performed within 5-30 days after onset of the first symptoms. Regions of interest (ROI) containing the area of infarction in the slices displaying enhanced radioactivity or the middle cerebral artery (MCA) region in four successive slices were defined for calculating enhancement ratios. The 99mTc leukocyte enhancement ratio (LER) and cobalt enhancement ratio (CER) were defined as the quotient of radioactivity in the ROI and an identical contralateral ROI. The MCA stroke-scale according to Orgogozo was used to assess neurological deficits at the time of scanning and discharge., Results: Cobalt-57 and 99mTc-HMPAO showed uptake in the infarcted brain area in five patients; the quantitative uptake in the infarcted brain area of the two tracers correlated significantly (p < 0.05). Both the LER and the CER correlated significantly (p < 0.05) with the Orgogozo score at the time of scanning. Only the LER correlated significantly (p < 0.05) with the Orgogozo score at discharge., Conclusion: Uptake of cobalt and leukocytes in the peri-infarct tissue suggests that 57Co may visualize a component of the inflammatory response. Divalent 57Co may be convenient to predict clinical prognosis after stroke.

Unlabelled: Carbon-11-methoxyprogabidic acid (11C-MPGA) was recently synthetized as a possible ligand for PET studies of gamma-amino-butyric acid (GABA) receptors in the brain. The data for human absorbed dose estimates are calculated based on the biodistribution of 11C-MPGA in mice and humans., Methods: Eighteen mice were killed at preset time intervals after an intravenous bolus injection of 3.7 MBq (100 microCi) 11C-MPGA. Time-activity curves were reconstructed for several organs. Three healthy men each had whole-body PET scans after an intravenous bolus injection of 37 MBq (1 mCi) to determine activity in the critical organs. Animal data were fitted into these human findings to calculate residence times, and the MIRDOSE 3 protocol was used to calculate the radiation absorbed dose., Results: Animal studies demonstrated a rapid distribution of 11C-MPGA in several organs. The highest activity was detected in the intestines, liver and kidneys. Brain activity was low throughout compared to these organs. The human whole-body study yielded similar results, with the intestines, liver and kidneys showing the highest activity. The estimated dose to the urinary bladder compartment turned out to be significant. The mean effective dose was 4.8 microSv/MBq (s.d.= 0.5 microSv/MBq)., Conclusion: PET studies using 185 MBq (5 mCi) 11C-MPGA are within the International Commission on Radiological Protection risk Category II for healthy volunteers.

Background: Vascular dementia (VaD) is an ill-defined entity. It is not known how acute brain failure related to stroke becomes chronic leading to dementia., Purpose: The present study investigates whether positron emission tomography (PET) can detect different metabolic patterns in VaD., Patients and Methods: Four groups of stroke patients were selected. The PET findings of 14 stroke patients with multiple large infarcts and dementia (MID) and 14 without dementia (MS) were compared. Sixteen stroke patients with lacunes, leukoaraiosis and dementia (LD) were assessed against nine without dementia (LS). The PET examination utilised the 15-O-steady-state technique in order to determine regional cerebral blood flow (rCBF), regional oxygen extraction rate (rOER) and regional cerebral metabolic rate for oxygen (rCMRO2) in different pre-established cortical, subcortical and cerebellar regions., Results: Decreased coupled mean rCBF and rCMRO2 with comparable rOER values were observed in all cerebral regions except in the cerebellum of the MID compared to the MS group. In the LD group mean rCBF and rCMRO2 were decreased with increased rOER in all cerebral regions except in the cerebellum compared to the LS group., Conclusions: The PET findings in demented patients with multiple large infarcts are in agreement with the concept of multi-infarct dementia. In demented patients with lacunes and leukoaraiosis, the PET pattern suggests a state of misery perfusion not only in the deep structures but also in the whole cerebral cortex. The present PET study argues that there are at least two possible mechanisms that can explain the occurrence of VaD in stroke patients.

Purpose: We compared the metabolic information obtained from single-voxel proton MR spectroscopy and positron emission tomography (PET) in patients with temporal lobe epilepsy., Methods: Twenty-nine patients with temporal lobe epilepsy were screened for metabolic abnormalities with both proton MR spectroscopy and PET. Lateralization with MR spectroscopy was possible by using NAA/(Cho+Cr) and an asymmetry index. Hypometabolism as determined by PET was classified as typical or complex., Results: Twenty-four (96%) of 25 patients whose seizure onset could be lateralized to one temporal lobe showed ipsilateral lateralization with either MR spectroscopy or PET, whereas concordant lateralization with both techniques was possible only in 14 (56%) of the 25 patients. MR spectroscopy showed 42 abnormal temporal lobes whereas PET showed only 25 lobes with decreased metabolism. All temporal lobes with hypometabolism at PET also had a low NAA/(Cho+Cr). Five patients (20%) with negative PET studies had seizures lateralized correctly with MR spectroscopy., Conclusion: Proton MR spectroscopy is more sensitive in depicting metabolic abnormalities than is PET in patients with temporal lobe epilepsy. Patients with negative PET studies will benefit from MR spectroscopy for the purpose of lateralization.

Positron emission tomography (PET) studies in dementia suffer from methodological differences. Most PET studies concern resting state metabolism in Alzheimer's disease and its correlations with neuropathology and neuropsychology. Only few clinically based PET studies on sensitivity and specificity of specific findings in specific dementing disorders have been reported. The role of PET in dementia for routine clinical purposes seems limited at present. Future studies should evaluate the potential of PET in preclinical diagnosis and to study treatment effects.

Neurotropin was found to reduce brain oedema in an experimental model of brain infarction in the guinea-pig. A randomized double-blind controlled trial with Neurotropin was performed in 220 patients admitted within 24 h after an acute ischemic stroke. 35 of the neurotropin and 41 of the placebo-randomized patients had to be excluded. 10 included patients in the neurotropin and 13 in the placebo-treated group died within the study period of 15 days. A better clinical outcome was observed in the 65 included surviving neurotropin compared with the 56 placebo-treated patients. The size of the infarct and of the oedema zones was significantly more decreased on CT scans from Day 11 compared with Day 3 after stroke in the neurotropin than in the placebo treated group. Neurotropin is helpful in treating brain oedema, related to acute ischemic stroke.

Time and dose dependency of paraoxon-induced myopathy in rats was studied in relation to esterase inhibition and clinical symptoms. High-dose poisoning resulted in a major cholinergic crisis with concomitant acetylcholinesterase inhibition in the first few hours with rapid restoration thereafter. Dose-dependent segmental muscle fiber necrosis occurred in clusters around the end-plates and was more frequent in diaphragms as compared to gastrocnemius muscles. However, in low-dose poisoned rats without major cholinergic symptoms or end-plate cholinesterase inhibition, necrotic fibers were also present. This indicates that not only end-plate cholinesterase inhibition but also neural or neuronal factors might be responsible for acetylcholine overflow and muscle fiber degeneration.